Drug
rimabotulinumtoxinB clinical trials
Also written MYOBLOC and botulinum toxin type B.
- studies test it
- 18
- open now
- 0
- in phase 3
- 6
- first study started
- 2001
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2003 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 9
- Phase 3
- 6
- Phase 4
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 9
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC (4) · Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC (3) · Gunma University (1) · University Hospital of North Norway (1) · Georgetown University (1) · Columbia University (1) · Eisai Co., Ltd. (1) · Eisai Limited (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses rimabotulinumtoxinB is read from its arms, and is right about nine times in ten.
Testing it · 18
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb SpasticityTerminatedPhase 2/3Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLCNCT04815967Written as Phase 2; Low Dose MYOBLOC (10,000 Units)
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb SpasticityTerminatedPhase 2/3Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLCNCT04099667Written as Phase 2; Low Dose MYOBLOC (15,000 Units)
- Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical DystoniaCompletedPhase 4Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLCNCT00702754Written as Botulinum Toxin Type B
- Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in AdultsCompletedPhase 3Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLCNCT02610868Written as MYOBLOC
- A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease PatientsCompletedPhase 2Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLCNCT00515437Written as Botulinum Toxin Type B (Myobloc)
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult SubjectsCompletedPhase 3Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLCNCT01994109Written as MYOBLOC
- Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric SubjectsWithdrawnPhase 3Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLCNCT05097079Written as MYOBLOC Low Dose
- Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic SclerosisCompletedPhase 2Gunma UniversityNCT03007004Written as Botulinum toxin type B (2500 units / vial)
- Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis SuppurativaCompletedNot applicableUniversity Hospital of North NorwayNCT03103074Written as Botulinum B Toxin
- Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal HyperhidrosisStatus unknownPhase 2Carl SwartlingNCT01930604Written as NeuroBloc/Myobloc (rimabotulinumtoxinB)
- Myobloc Atrophy StudyCompletedPhase 4Georgetown UniversityNCT02052024Written as MYOBLOC
- Quantifying Musical Performance After Treatment With Myobloc in Musician's DystoniaCompletedPhase 4Columbia UniversityNCT00208091Written as Botulinum toxin, type B
- Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic TorticollisCompletedPhase 2Eisai Co., Ltd.NCT00165776Written as BOTULINUM TOXIN TYPE B
- An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian SubjectsCompletedPhase 2Eisai LimitedNCT00280384Written as E2014 (Botulinum toxin type B)
- Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated SweatingCompletedPhase 1Henry M. Jackson Foundation for the Advancement of Military MedicineNCT01671800Written as Botulinum Type B
- Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2/3The University of Texas Health Science Center at San AntonioNCT00125203Written as Botulinum toxin type B (Myobloc)
- Pilot Study to Assess the Efficacy of Botulinum Toxin B on Pain and Disability in Subjects With Acute Low Back PainTerminatedPhase 4United States Department of DefenseNCT00384579Written as Botulinum toxin B
- "DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?"CompletedPhase 1/2Stanford UniversityNCT00238641Written as Botulinum Toxin type B
Codes
What other systems call rimabotulinumtoxinB · ClinicalTrials.gg INT003872
- MeSH (NLM) C096323rimabotulinumtoxinBConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0Y70779M1FRIMABOTULINUMTOXINBConfirmed FDA, NLM
- RxNorm 860178One source FDA
- NCI Thesaurus C87453RimabotulinumtoxinbOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C096323 | rimabotulinumtoxinB | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0Y70779M1F | RIMABOTULINUMTOXINB | Confirmed FDA, NLM |
| RxNorm | 860178 | — | One source FDA |
| NCI Thesaurus | C87453 | Rimabotulinumtoxinb | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.